Intelligent Bio Solutions Inc. Expands Forensic Market Reach with Innovative Drug Screening Technology

The collaboration between Intelligent Bio Solutions Inc. (INBS) and SMARTOX marks a significant milestone in the forensic and drug testing industry, highlighting the shift towards more efficient and dignified testing methods. With over 50 INBS Intelligent Fingerprinting Drug Screening Readers deployed and more than 7,000 tests conducted, including over 1,500 in 2024 alone, the partnership underscores the increasing adoption of INBS's innovative technology. This rapid, non-invasive testing solution, which analyzes fingerprint sweat, offers a compelling alternative to traditional urine and saliva tests, particularly in corrections, rehabilitation, and drug court settings.

The implications of this expansion are profound, not only for the forensic market but also for the broader drug testing industry. The technology's ability to deliver results in under ten minutes, with minimal invasion of privacy, represents a significant advancement in drug screening. Furthermore, INBS's pursuit of FDA clearance for its codeine opiate test and plans to enter the workplace drug testing sector later this year could revolutionize how employers in safety-critical industries conduct drug screenings. This move could lead to wider acceptance and integration of fingerprint sweat-based testing across various sectors, enhancing workplace safety and efficiency.

The partnership between INBS and SMARTOX is a testament to the growing recognition of the need for more humane and efficient drug testing solutions. As the demand for such technologies continues to rise, the potential for broader applications beyond the forensic market becomes increasingly apparent. This development not only benefits the companies involved but also sets a new standard for drug testing, offering a glimpse into the future of non-invasive medical technologies.